ChemicalBook
Chinese Japanese Germany

4,4'-Diaminodiphenylsulfone

4,4'-Diaminodiphenylsulfone
4,4'-Diaminodiphenylsulfone
CAS No.
80-08-0
Chemical Name:
4,4'-Diaminodiphenylsulfone
Synonyms
DDS;K509;wr448;DADPS;1358F;f1358;DADDS;Udolac;WR 448;EPORAL
CBNumber:
CB0152851
Molecular Formula:
C12H12N2O2S
Formula Weight:
248.3
MOL File:
80-08-0.mol

4,4'-Diaminodiphenylsulfone Properties

Melting point:
175-177 °C(lit.)
Density 
1.2701 (rough estimate)
refractive index 
1.5950 (estimate)
storage temp. 
-20°C Freezer
solubility 
0.38g/l
form 
Crystalline Powder
pka
pKb 13.0(at 25℃)
color 
White to beige
PH
5.5-7.5 (H2O, 20℃)(saturated aqueous solution)
Water Solubility 
<0.1 g/100 mL at 20 ºC
Merck 
14,2822
BRN 
788055
Stability:
Stable. Combustible. Incompatible with strong oxidizing agents.
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
CAS DataBase Reference
80-08-0(CAS DataBase Reference)
NIST Chemistry Reference
Dapsone(80-08-0)
EPA Substance Registry System
Benzenamine, 4,4'-sulfonylbis-(80-08-0)
SAFETY
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  Xn
Risk Statements  22
Safety Statements  22
RIDADR  3249
WGK Germany  1
RTECS  BY8925000
TSCA  Yes
HazardClass  6.1(b)
PackingGroup  III
HS Code  29051620
HS Code  29309070
Hazardous Substances Data 80-08-0(Hazardous Substances Data)
Toxicity LD50 orally in Rabbit: 1000 mg/kg LD50 dermal Rabbit > 4000 mg/kg
Symbol(GHS):
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning P264, P270, P301+P312, P330, P501
H320 Causes eye irritation Serious eye damage/eye irritation Category 2B Warning P264, P305+P351+P338,P337+P313
H370 Causes damage to organs Specific target organ toxicity, single exposure Category 1 Danger P260, P264, P270, P307+P311, P321,P405, P501
H372 Causes damage to organs through prolonged or repeated exposure Specific target organ toxicity, repeated exposure Category 1 Danger P260, P264, P270, P314, P501
Precautionary statements:
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P307+P311 IF exposed: call a POISON CENTER or doctor/physician.
P405 Store locked up.
P501 Dispose of contents/container to..…

4,4'-Diaminodiphenylsulfone price More Price(15)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 46158 Dapsone VETRANAL , analytical standard 80-08-0 250mg $45.3 2018-11-13 Buy
Sigma-Aldrich 1164008 Dapsone United States Pharmacopeia (USP) Reference Standard 80-08-0 200mg $348 2018-11-13 Buy
TCI Chemical D0089 Bis(4-aminophenyl) Sulfone >98.0%(HPLC)(T) 80-08-0 25g $24 2018-11-22 Buy
TCI Chemical D0089 Bis(4-aminophenyl) Sulfone >98.0%(HPLC)(T) 80-08-0 100g $54 2018-11-22 Buy
Alfa Aesar A18976 4,4'-Diaminodiphenyl sulfone, 98% 80-08-0 100g $41.3 2018-11-13 Buy

4,4'-Diaminodiphenylsulfone Chemical Properties,Uses,Production

Chemical Properties

Off -White Crystalline Solid

Uses

An antibacterial used in the treatment of dermatitis herpetiformis

Uses

antibacterial, leprostatic, dermatitis herpetiformis suppressant

Uses

4,4'-diaminodiphenylsulfone be used for preparation polyimide and epoxy resin material.

Definition

ChEBI: A sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacteriu leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.

Uses

Hardening agent in the curing of epoxy resins.

brand name

Hansolar (ParkeDavis).

Antimicrobial activity

Dapsone is active against many bacteria and some protozoa. Fully susceptible strains of M. leprae are inhibited by a little as 0.003 mg/L. It is predominantly bacteristatic. Resistance is associated with mutations in the folP1 gene involved in the synthesis of para-aminobenzoic acid.

Acquired resistance

Resistance to high levels is acquired by several sequential mutations. As a result of prolonged use of dapsone monotherapy, acquired resistance emerged in patients with multibacillary leprosy in many countries. Initial resistance also occurs in patients with both paucibacillary and multibacillary leprosy. Thus, leprosy should always be treated with multidrug regimens. Resistance of M. leprae to dapsone (and other anti-leprosy drugs) may now be determined by use of DNA microarrays.

General Description

Odorless white or creamy white crystalline powder. Slightly bitter taste.

Air & Water Reactions

Sensitive to oxidation and light. Insoluble in water.

Reactivity Profile

4,4'-Diaminodiphenylsulfone can neutralize acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated in combination with strong reducing agents, such as hydrides. Incompatible with strong oxidizing agents. Also incompatible with epoxy resins under uncontrolled conditions .

Fire Hazard

4,4'-Diaminodiphenylsulfone is probably combustible.

Pharmaceutical Applications

The most effective of a number of sulfonamide derivatives to be tested against leprosy. The dry powder is very stable. It is only slightly soluble in water.

Pharmacokinetics

Oral absorption: >90%
Cmax 100 mg oral: c. 2 mg/L after 3–6 h
Plasma half-life: 10–50 h
Plasma protein binding: c. 50%
It is slowly but almost completely absorbed from the intestine and widely distributed in the tissues, but selectively retained in skin, muscle, kidneys and liver. It is metabolized by N-oxidation and also by acetylation, which is subject to the same genetic polymorphism as isoniazid. The elimination half-life is consequently very variable, but on standard therapy the trough levels are always well in excess of inhibitory concentrations. It is mostly excreted in the urine: in the unchanged form (20%), as N-oxidation products (30%) and as a range of other metabolites.

Clinical Use

Leprosy (multidrug regimens)
Prophylaxis of malaria, treatment of chloroquine-resistant malaria (in combination with pyrimethamine)
Prophylaxis of toxoplasmosis (in combination with pyrimethamine)
Prophylaxis (monotherapy) and treatment (in combination with trimethoprim) of Pneumocystis jirovecii pneumonia
Dermatitis herpetiformis and related skin disorders

Side effects

Although usually well tolerated at standard doses, gastrointestinal upsets, anorexia, headaches, dizziness and insomnia may occur. Less frequent reactions include skin rashes, exfoliative dermatitis, photosensitivity, peripheral neuropathy (usually in non-leprosy patients), tinnitus, blurred vision, psychoses, hepatitis, nephrotic syndrome, systemic lupus erythematosus and generalized lymphadenopathy.
The term ‘dapsone syndrome’ is applied to a skin rash and fever occurring 2–8 weeks after starting therapy and sometimes accompanied by lymphadenopathy, hepatomegaly, jaundice and/or mononucleosis.
Blood disorders include anemia, methemoglobinemia, sulfhemoglobinemia, hemolysis (notably in patients with glucose- 6-phosphate dehydrogenase deficiency), mononucleosis, leukopenia and, rarely, agranulocytosis. Severe anemia should be treated before patients receive dapsone.
The incidence of adverse reactions declined in the 1960s but reappeared around 1982 when multidrug therapy was introduced, and may represent an unexplained interaction with rifampicin.

Safety Profile

Poison by ingestion, intraperitoneal, and subcutaneous routes. Human systemic effects by ingestion: agranulocytosis, change in tubules and other kidney changes, cyanosis, effect on joints, hemolysis with or without anemia, jaundice, methemoglobinemiacarboxyhemoglobinemia, retinal changes, somnolence. Experimental reproductive effects. Can cause hepatitis, dermatitis, and neuritis. Questionable carcinogen with experimental carcinogenic and neoplastigenic data. Human mutation data reported. Used in leprosy treatment and veterinary medicine. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also SULFONATES.

4,4'-Diaminodiphenylsulfone Preparation Products And Raw materials

Raw materials

Preparation Products


4,4'-Diaminodiphenylsulfone Suppliers

Global( 307)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 22049 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20786 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32651 55
Hubei Jusheng Technology Co.,Ltd.
86-155-27864001
peter@hubeijusheng.com CHINA 18004 58
Haihang Industry Co.,Ltd
86-531-88032799
+86 531 8582 1093 export@haihangchem.com CHINA 4529 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 10967 58
Yancheng Green Chemicals Co.,Ltd
86-515-87883661
86-515-87883652 sales@greenchem-china.com CHINA 350 58
Hebei Huanhao Biotechnology Co., Ltd.
86-0311-83975816
86-0311-83975816 lisa@hbhuanhao.com CHINA 676 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 19990 58

View Lastest Price from 4,4'-Diaminodiphenylsulfone manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-10-30 4,4'-Diaminodiphenylsulfone
80-08-0
US $120.00 / G 10MG 99.6% 600kg/month Hebei Huanhao Biotechnology Co., Ltd.
2018-08-15 4,4'-Diaminodiphenylsulfone
80-08-0
US $2.00 / KG 1KG 98% 1ton career henan chemical co

4,4'-Diaminodiphenylsulfone Spectrum


80-08-0(4,4'-Diaminodiphenylsulfone)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved